StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$75.95−2.25 (-2.88%)

Close on Nov 18, 2026Market cap $3.33BP/E –Yield 0.00%

Tarsus Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Tarsus Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$48.54M. For fiscal 2025 it was -$70.97M. The highest annual figure on record is -$4.30M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$70.97M–
FY2024Dec 31, 2024-$120.57M–
FY2023Dec 31, 2023-$143.16M–
FY2022Dec 31, 2022-$62.71M–
FY2021Dec 31, 2021-$12.16M–
FY2020Dec 31, 2020-$27.00M–
FY2019Dec 31, 2019-$4.30M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.91M–
Q1 FY2026Mar 31, 2026-$6.12M–
Q4 FY2025Dec 31, 2025-$7.98M–
Q3 FY2025Sep 30, 2025-$14.53M–
Q2 FY2025Jun 30, 2025-$22.18M–
Q1 FY2025Mar 31, 2025-$26.28M–
Q4 FY2024Dec 31, 2024-$24.42M–
Q3 FY2024Sep 30, 2024-$25.16M–
Q2 FY2024Jun 30, 2024-$33.30M–
Q1 FY2024Mar 31, 2024-$37.68M–
Q4 FY2023Dec 31, 2023-$44.45M–
Q3 FY2023Sep 30, 2023-$40.94M–
Q2 FY2023Jun 30, 2023-$32.82M–
Q1 FY2023Mar 31, 2023-$24.95M–
Q4 FY2022Dec 31, 2022-$15.06M–
Q3 FY2022Sep 30, 2022-$22.91M–
Q2 FY2022Jun 30, 2022-$5.22M-171.7%
Q1 FY2022Mar 31, 2022-$19.52M-282.2%
Q4 FY2021Dec 31, 2021-$14.45M–
Q3 FY2021Sep 30, 2021-$15.71M–
Q2 FY2021Jun 30, 2021$7.28M–
Q1 FY2021Mar 31, 2021$10.71M–
Q4 FY2020Dec 31, 2020-$11.48M–
Q3 FY2020Sep 30, 2020-$10.14M–
Q2 FY2020Jun 30, 2020-$3.26M–
Q1 FY2020Mar 31, 2020-$2.12M–
Q4 FY2019Dec 31, 2019-$1.08M–
Q3 FY2019Sep 30, 2019-$633.00K–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?